FDA and CDC officials stress Johnson & Johnson vaccine side effects are ‘extremely rare’
Johnson & Johnson pause ‘will not have a significant impact’ on US vaccine plan, White House says
Johnson & Johnson Covid vaccine to be paused in US over rare blood clots
US health agencies have recommended states pause administration of the Johnson & Johnson coronavirus vaccine, after reports of rare and severe blood clots emerged in six women. More than 6.8m doses have been administered nationally.
The concerns mirror those of drugs agencies in Europe and Australia over the AstraZeneca vaccine. That vaccine is not authorized in the US, and there have been no significant safety concerns raised about the two other vaccines that makeup the majority of US supply, from Pfizer-BioNTech and Moderna.
“People who have received the J&J vaccine who develop severe headache, abdominal pain, leg pain, or shortness of breath within three weeks after vaccination should contact their health care provider,” the Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) said in a joint statement.
All six women were between the ages of 18 and 48. One woman died, and a woman in Nebraska is hospitalized in critical care, according to the New York Times. Johnson & Johnson’s vaccine is also under scrutiny by the European Medicines Agency, which is investigating four cases of clotting.
Because US states control their own health response, the health agencies framed their statement as a recommendation, even as federal sites will immediately pause administration of the vaccine.